Ibrutinib (ibr), a first-in-class BTK inhibitor, has demonstrated high response rates in both relapsed/refractory and treatment naïve chronic lymphocytic leukemia (CLL) [1, 2]. Here, BTK is linked to B-cell chronic lymphocytic leukemia.